【TMCLIFE 0101 交流专区】TMC生命科学

icy97

新加坡康盛医院股东-1对1比例换rsp控股股权
http://www.chinapress.com.my/20181112/新加坡康盛医院股东-1对1比例换rsp控股股权/

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Proposed Distribution in Specie by way of Capital Reduction
The Board of Directors of TMC Life Sciences Berhad ("the Company") wishes to inform that TMGL, the holding company has on 12 November 2018 released an announcement to Singapore Exchange pertaining to proposing to distribute its entire interests in its design and engineering and hospitality businesses to its shareholders via a distribution in specie by way of a capital reduction . This announcement is dated 12 November 2018. http://www.bursamalaysia.com/market/listed-companies/company-announcements/5970293

icy97

TMC LIFE SCIENCES BERHAD

EX-date	11 Feb 2019
Entitlement date	13 Feb 2019
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final Single-Tier Dividend of 0.183 sen per ordinary share in respect of the financial year ended 31 August 2018.
Period of interest payment	to
Financial Year End	31 Aug 2018
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200 Kuala LumpurTel:03-27839299Fax:03-27839222
Payment date	27 Feb 2019
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	13 Feb 2019
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0018

icy97

Date of change	25 Jan 2019
Name	MR ROY QUEK HONG SHENG
Age	48
Gender	Male
Nationality	Singapore
Designation	Director
Directorate	Executive
Type of change	Resignation
Reason	Part of Thomson Medical Group Limited's strategy to put in place strong local leadership as it prepares for its next phase of rapid growth and development.

icy97

Date of change	25 Jan 2019
Name	CIK WAN NADIAH BINTI WAN MOHD ABDULLAH YAAKOB
Age	34
Gender	Female
Nationality	Malaysia
Designation	Executive Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	MSc Public Health Nutrition	London School of Hygiene and Tropical Medicine, UK
2	Others	AB cumLaude in Biochemical Sciences	Harvard College

Working experience and occupation

Ms. Wan Nadiah Binti Wan Mohd Abdullah Yaakob ("Ms. Nadiah Wan"), was appointed as Chief Executive Officerof Thomson Hospitals Sdn Bhd and Group Chief Corporate Officer of TMC Life Sciences Berhad on 19 June 2017.Prior to joining Thomson Hospitals Sdn Bhd and the Company, Ms. Nadiah Wan worked in Sunway Medical Centre as Chief Operating Officer (Clinical Services) after being promoted from Director of Business Development and Corporate Communications in October 2016. She started her career at The Boston Consulting Group in 2007 as an Associate Consultant before joining Sunway Group as Manager, Strategy and Corporate Development in 2010.

icy97

Date of change	01 Feb 2019
Name	MR KAN KHEONG NG
Age	63
Gender	Male
Nationality	Malaysia
Type of change	Redesignation
Previous Position	Non Executive Director
New Position	Executive Director
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Business Administration	Royal Melbourne Institute of Technology

Working experience and occupation

Mr. Kan Kheong Ng ("Mr. Barry Kan") was appointed as the Non Independent Non-Executive Director of TMC Life Science Berhad on 2 June 2015. He is a veteran of almost 30 years in the automotive industry with rich and vast experience in managing various illustrious global brands during his career with renowned regional dealership, Wearnes Automotive, headquartered in Singapore. Prior to that, he was with the Port Authority of Singapore for 7 years. As General Manager at Malayan Motors (a division then of Wearnes Automotive Pte Ltd), his portfolio included the Rolls-Royce, Bentley, Jaguar and Volvo Trucks franchises in Singapore. He was also responsible for theintroduction of some of the brands into new territories such as Brunei, Indonesia, Taiwan and Thailand. In addition to the strategic management of the business, he took personal interest in Customer Relationship Management and Aftersales operations, which resulted in a high level of clientele retention for the luxury automotive brands.Promoted to Managing Director of the Prestige Division of Wearnes Automotive, he was instrumental in the acquisition of new brands which included Bugatti, Land Rover and McLaren. He was also the key representative of the company for the high-society clientele which included the Captains of Industry as well as esteemed members of Royal families within the region.When the exciting opportunity arose to develop the integrated automotive hub in Nusajaya, Iskandar Malaysia, he joined Fastrack Autosports (Iskandar) Pte. Ltd. to conceptualise and execute the project, in partnership with UEW Sunrise Berhad. Mr. Kan leads the joint venture company, Fastrack Iskandar Sdn. Bhd. as its Chief Executive Officer.

icy97

Type	Announcement
Subject	OTHERS
Description	Press Release
Please refer to the Press Release dated 23 January 2019. Please refer attachment below.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6044045

Attachments Press Release - New Board Appointments (23 Jan 2019).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Nov 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Nov 2018	30 Nov 2017	30 Nov 2018	30 Nov 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	47,164	41,728	47,164	41,728
2	Profit/(loss) before tax	9,406	8,324	9,406	8,324
3	Profit/(loss) for the period	7,070	6,329	7,070	6,329
4	Profit/(loss) attributable to ordinary equity holders of the parent	7,070	6,329	7,070	6,329
5	Basic earnings/(loss) per share (Subunit)	0.41	0.36	0.41	0.36
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4300		0.4300

icy97

Date of change	01 Feb 2019
Name	MR WILSON SAM
Age	42
Gender	Male
Nationality	Singapore
Designation	Alternate Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Bachelor of Business Studies (Honours) with a major in financial analysis and a minor in accountancy	Nanyang Technological University

Working experience and occupation

Mr. Sam ("Mr. Sam") has close to 20 years of experience in investments, advisory and financial analysis and is currently the Senior Vice President of Kestrel Capital Pte. Ltd., a Singapore headquartered private investment company, where he heads the investments and merger and acquisitions team. Recent notable transactions include the acquisition of Valencia Club de Futbol, the initial public offering of Secura Group and the very substantial acquisition of Sasteria Pte. Ltd. Mr. Sam was the Vice President of Rowsley Limited where he managed its investment activities before joining Kestrel Capital Pte Ltd in 2013.Prior to this, Mr. Sam held various positions with regional and international banks, specialising in corporate finance and merger and acquisitions and was involved in numerous initial public offerings, financial advisory and merger and acquisition transactions. He started his career as a senior officer in a Singapore government statutory board in 2000 before joining a US multinational company in 2001.Mr. Sam is also a director of Mint Media Sports Limited, a sports entertainment and media company and Catpital Private Limited, an investment company.

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")-Unaudited 4th Quarter Financial Statement Announcement for the Financial Period Ended 31 December 2018
The Board of Directors of TMC Life Sciences Berhad (“The Company”) wishes to inform that Thomson Medical Group Limited (“TMGL”), the holding company of the Company had announced the Unaudited 4th Quarter Financial Statement Announcement for the Financial Period Ended 31 December 2018. Please refer to the below announcement on the website of Singapore Exchange released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/6082889 This announcement is dated 28 February 2019

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Memorandum of Understanding
The Board of Directors of TMC Life Sciences Berhad ("the Company") wishes to inform that TMGL, the holding company has on 12 March 2019 released an announcement to Singapore Exchange pertaining to TMGL has on 7 March 2019 entered into a Memorandum of Understanding with Brigham Health International, LLC ("BHI") and Dana-Farber Cancer Institute, Inc., ("DFCI") in relation to exploring a potential collaboration to support the growth and advancement of Thomson Medical's hospital projects in the region and to promote the advancement of healthcare delivery, education and research with a focus on women's health and oncology. Please refer to the below announcement on the website of Singapore Exchange which released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/6094313 This announcement is dated 13 March 2018.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 28 Feb 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		28 Feb 2019	28 Feb 2018	28 Feb 2019	28 Feb 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,160	39,711	92,324	81,439
2	Profit/(loss) before tax	8,223	6,403	17,629	14,727
3	Profit/(loss) for the period	6,206	4,760	13,276	11,089
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,206	4,760	13,276	11,089
5	Basic earnings/(loss) per share (Subunit)	0.36	0.27	0.76	0.64
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4300		0.4300

icy97

Expiry/Maturity of the securities

TMC LIFE SCIENCES BERHAD

Instrument Category	Securities of PLC
Instrument Type	Warrants
Type Of Expiry	Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion price	Cash
Exercise/ Strike/ Conversion Price	Malaysian Ringgit (MYR) 0.7500
Exercise/ Conversion Ratio	1:1
Settlement Type / Convertible into	Physical (Shares)
Last Date & Time of Trading	03 Jun 2019 05:00 PM
Date & Time of Suspension	04 Jun 2019 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c	14 Jun 2019 04:00 PM
Date & Time of Expiry	21 Jun 2019 05:00 PM
Date & Time for Delisting	24 Jun 2019 09:00 AM

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6162993

Attachments Notice to Warrantholders - Expiry of Warrants 2015-2019.pdf

icy97

tmc生科第三季赚836万
http://www.enanyang.my/news/20190730/tmc生科第三季赚836万/

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 May 2019	31 May 2018	31 May 2019	31 May 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	51,130	44,406	143,454	125,845
2	Profit/(loss) before tax	10,888	7,997	28,517	22,724
3	Profit/(loss) for the period	8,357	5,627	21,633	16,716
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,357	5,627	21,633	16,716
5	Basic earnings/(loss) per share (Subunit)	0.48	0.32	1.25	0.96
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4300

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Aug 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Aug 2019	31 Aug 2018	31 Aug 2019	31 Aug 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	51,524	43,194	194,978	169,039
2	Profit/(loss) before tax	9,634	10,373	38,151	33,097
3	Profit/(loss) for the period	6,463	11,080	28,096	27,796
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,463	11,080	28,096	27,796
5	Basic earnings/(loss) per share (Subunit)	0.37	0.64	1.62	1.60
6	Proposed/Declared dividend per share (Subunit)	0.20	0.18	0.20	0.18
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4300

icy97

Change in Financial Year End

TMC LIFE SCIENCES BERHAD

Old financial year end	31 Aug 2020
New financial year end	30 Jun 2020

Remarks :

The Board of Directors of TMC Life Sciences Berhad ('the Company') had approved the change in the financial year end ('FYE') of the Company from 31 August to 30 June. The next set of Audited Financial Statements shall be for a period of 10 months from 1 September 2019 to 30 June 2020 and thereafter, the FYE shall be 30 June for each subsequent year. The change in the FYE of the Company from 31 August to 30 June annually is to coincide with the FYE of its holding company.

icy97

Type	Announcement
Subject	OTHERS
Description	TMC Life Sciences Berhad ('the Company') - Proposed Single-Tier Final Dividend
The Board of Directors of the Company has proposed a single-tier final dividend of 2.013% or 0.2013 sen per ordinary share for the financial year ended 31 August 2019 subject to the shareholders' approval at the forthcoming Seventeenth Annual General Meeting of the Company. The entitlement and payment dates of the aforesaid dividend will be announced at a later date. This announcement is dated 24 October 2019.

icy97

TMC LIFE SCIENCES BERHAD

Entitlement subject	Final Dividend
Entitlement description	Single-Tier Final Dividend of 0.2013 sen per Ordinary Share
Ex-Date	06 Mar 2020
Entitlement date	09 Mar 2020
Entitlement time	5:00 PM
Financial Year End	31 Aug 2019
Period
Share transfer book & register of members will be	to  closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	25 Mar 2020
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	09 Mar 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0020

icy97

Type	Announcement
Subject	OTHERS
Description	VARIANCE OF UNAUDITED RESULTS AS ANNOUNCED ON 23 OCTOBER 2019 AND THE AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 AUGUST 2019
1. INTRODUCTION The Board of Directors of the Company wishes to announce that the Company had on 24 October 2019 submitted its unaudited results for the year ended 31 August 2019 (“4Q FYE 2019’’) to Bursa Malaysia Securities Berhad (“Bursa Securities’’). 2. DEVIATION BETWEEN UNAUDITED RESULTS AND THE AUDITED RESULTS In compliance with Paragraph 9.19(35) of the Main Market Listing Requirements of Bursa Securities, the Company wishes to inform that the deviation in results of more than 10% between the profit after tax attributable to owners of the Company as announced in 4Q FYE 2019 results on 24 October 2019 and the audited financial statements for the financial year ended 31 August 2019 (“AFS 2019”) was mainly due to the accounting for additional deferred tax liability that arose due to the change in the rate of Real Property Gains Tax from 5% to 10%. The deviation is reconciled and explained as below: Group Variance 4Q FYE 2019 AFS 2019 Amount Percentage RM’000 RM’000 RM’000 % Profit attributable to: Owners of the Company 28,096 20,919 7,177 26% Total comprehensive income attributable to: Owners of the Company 28,093 20,916 7,177 26% Reconciliation of deviation Group RM’000 Profits attributable to owners of the Company as per 4Q FYE 2019 28,096 Additional deferred tax liability (7,177) Profits attributable to owners of the Company as per AFS 2019 (Audited) 20,919 Total comprehensive income attributable to owners of the Company as per 4Q FYE 2019 28,093 Additional deferred tax liability (7,177) Total comprehensive income attributable to owners of the Company as per AFS 2019 (Audited) 20,916 The Group completed the acquisition of BB Waterfront Sdn. Bhd. (“BBWF”) in June 2015. The acquisition of BBWF was accounted for as an acquisition of business in accordance with the requirements of MFRS 3. At the Group level, the freehold land of BBWF was measured at fair value and a corresponding deferred tax liability was recorded to account for the difference between the fair value and the book value. The deferred tax liability was computed using the Real Property Gains Tax Rate of 5%. The variance above is solely due to accounting for additional deferred tax liability that arose due to the change in the rate of Real Property Gains Tax from 5% to 10%. The Board was informed by our external auditors in December 2019 of the requirements to make this adjustment. This adjustment is made to comply with the requirements of MFRS 112. It has no impact on the Group’s business operations, cash flows and the ability to distribute dividends. This announcement is dated 18 December 2019.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3010568

Attachments TMCLS 19 AFS.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Nov 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		Three Months	Three Months	Three Months	Three Months
		01 Sep 2019 To	01 Sep 2018 To	01 Sep 2019 To	01 Sep 2018 To
		30 Nov 2019	30 Nov 2018	30 Nov 2019	30 Nov 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	52,534	0	52,534	0
2	Profit/(loss) before tax	10,665	0	10,665	0
3	Profit/(loss) for the period	7,953	0	7,953	0
4	Profit/(loss) attributable to ordinary equity holders of the parent	7,953	0	7,953	0
5	Basic earnings/(loss) per share (Subunit)	0.46	0.00	0.46	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4400

icy97

Type	Announcement
Subject	OTHERS
Description	THOMSON HOSPITALS SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF TMC LIFE SCIENCES BERHAD - ACCEPTANCE OF NON-REVOLVING LINE INDUSTRIAL HIRE PURCHASE OF UP TO RM90.0 MILLION FROM OCBC BANK (MALAYSIA) BERHAD
1. INTRODUCTION The Board of Directors of TMC Life Sciences Berhad (“TMCLS” or “the Company”) wishes to announce that its wholly-owned subsidiary, Thomson Hospitals Sdn. Bhd., has accepted a Non-Revolving Line Industrial Hire Purchase of up to RM90.0 million (“the Facility”) with OCBC Bank (Malaysia) Berhad (“the Bank”) on 13 January 2020 based on terms and conditions as contained in the Bank’s the Letter of Offer dated 16 August 2019 and Supplemental Letter of Offer dated 12 December 2019. 2. INFORMATION OF THE FACILITY Facility type and Amount: Non-Revolving Line Industrial Hire Purchase of up to RM90.0 million. Purpose of the Facility: To hire the equipment/goods (as applicable) approved by the Bank. Securities to be provided: A corporate guarantee from TMCLS in favour of the Bank. 3. FINANCIAL EFFECT OF THE FACILITY The Facility (when fully drawn) is expected to increase the gearing of the Group. For illustrative purposes, based on the audited consolidated financial statements of the Company for the financial year ended 31 August 2019, the Facility is expected to increase the gearing of the Group from 0.002 times to 0.12 times. The Board of Directors of the Company does not envisage any specific risk associated with the acceptance of the Facility, apart from the financing costs. 4. INTERESTS OF DIRECTORS, SUBSTANTIAL SHAREHOLDERS AND PERSONS CONNECTED None of the Directors and/or substantial shareholders of the Company and persons connected to them have any interest, direct or indirect, in the Facility. 5. DIRECTORS’ RECOMMENDATION The Board of Directors, after careful deliberation, is of the opinion that the acceptance of the Facility is in the best interest of the Company and TMCLS Group. This announcement is dated 14 January 2020.